EA200701211A1 - Полипептиды, которые связываются с br3, и их применение - Google Patents
Полипептиды, которые связываются с br3, и их применениеInfo
- Publication number
- EA200701211A1 EA200701211A1 EA200701211A EA200701211A EA200701211A1 EA 200701211 A1 EA200701211 A1 EA 200701211A1 EA 200701211 A EA200701211 A EA 200701211A EA 200701211 A EA200701211 A EA 200701211A EA 200701211 A1 EA200701211 A1 EA 200701211A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- polypeptides
- binding
- application
- methods
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Abstract
Настоящее изобретение относится к новым BR3-связывающим антителам и полипептидам, включающим антагонистические и агонистические полипептиды. Настоящее изобретение также относится к использованию BR3-связывающих антител и полипептидов, например, в способах лечения, скрининга, диагностики, в методах тестирования и очистки белков.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64032304P | 2004-12-31 | 2004-12-31 | |
PCT/US2005/047072 WO2006073941A2 (en) | 2004-12-31 | 2005-12-23 | Polypeptides that bind br3 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200701211A1 true EA200701211A1 (ru) | 2007-12-28 |
Family
ID=36588679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200701211A EA200701211A1 (ru) | 2004-12-31 | 2005-12-23 | Полипептиды, которые связываются с br3, и их применение |
Country Status (14)
Country | Link |
---|---|
US (2) | US20080181888A1 (ru) |
EP (1) | EP1838735A2 (ru) |
JP (1) | JP2008526205A (ru) |
KR (1) | KR20070107687A (ru) |
CN (1) | CN101120021A (ru) |
AP (1) | AP2007004034A0 (ru) |
AU (1) | AU2005323025A1 (ru) |
BR (1) | BRPI0518994A2 (ru) |
CA (1) | CA2595112A1 (ru) |
EA (1) | EA200701211A1 (ru) |
IL (1) | IL183353A0 (ru) |
MX (1) | MX2007008017A (ru) |
NO (1) | NO20072721L (ru) |
WO (1) | WO2006073941A2 (ru) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
US20110129414A1 (en) * | 2005-11-15 | 2011-06-02 | Balyasnikova Irina V | Single Chain Fragment of Monoclonal Antibody 9B9 and Uses Thereof |
CA2629715C (en) * | 2005-11-18 | 2016-05-03 | Glenmark Pharmaceuticals S.A. | Anti-alpha2 integrin antibodies and their uses |
WO2007062090A2 (en) | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
GB0612928D0 (en) * | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
WO2008008482A2 (en) * | 2006-07-13 | 2008-01-17 | Genentech, Inc. | Altered br3-binding polypeptides |
GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
WO2008098145A1 (en) * | 2007-02-07 | 2008-08-14 | University Of Washington | Methods for modulating antigen-specific b cell responses |
WO2008100805A2 (en) * | 2007-02-09 | 2008-08-21 | Genentech, Inc. | Anti-robo4 antibodies and uses therefor |
PE20140614A1 (es) | 2007-07-16 | 2014-05-28 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados |
CA2692819A1 (en) | 2007-07-16 | 2009-01-22 | Genentech, Inc. | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
SG10201704689XA (en) | 2008-01-18 | 2017-07-28 | Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
SI2247620T1 (sl) | 2008-01-31 | 2016-09-30 | Genentech, Inc. | Protitelesa proti CD79b in imunokonjugati in postopki za uporabo |
GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
JP5767109B2 (ja) * | 2008-07-17 | 2015-08-19 | ノバルティス アーゲー | 治療抗体を用いる組成物及び方法 |
EP2352521B1 (en) | 2008-10-14 | 2020-09-16 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
WO2010059315A1 (en) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
BRPI0918204A2 (pt) | 2008-12-23 | 2015-12-08 | Genentech Inc | igv variante composição farmaceutica e kit |
ES2572728T3 (es) | 2009-03-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Anticuerpos anti-HER biespecíficos |
US20110064732A1 (en) | 2009-09-17 | 2011-03-17 | Sanne Lysbet De Haas | Methods and compositions for diagnostic use in cancer patients |
WO2011041336A2 (en) | 2009-09-30 | 2011-04-07 | Genentech, Inc. | Methods of treating cancer using notch antagonists |
ES2565208T3 (es) | 2009-12-11 | 2016-04-01 | F. Hoffmann-La Roche Ag | Anticuerpos anti-VEGF-C y métodos de uso de los mismos |
US20110171231A1 (en) * | 2010-01-12 | 2011-07-14 | Carlos Bais | ANTI-PlGF ANTIBODIES AND METHODS USING SAME |
SG10201501342UA (en) | 2010-02-24 | 2015-04-29 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
CN101851278B (zh) * | 2010-05-26 | 2013-03-13 | 石药集团中奇制药技术(石家庄)有限公司 | B细胞激活因子拮抗剂及其制备方法与用途 |
AU2011280997A1 (en) | 2010-07-23 | 2013-02-28 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
US20130203624A1 (en) | 2010-07-23 | 2013-08-08 | President And Fellows Of Harvard College | Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions |
WO2012012704A2 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting kidney-associated diseases or conditions |
MX361944B (es) | 2010-07-23 | 2018-12-19 | President And Fellows Of Harvard College Star | Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales. |
JP2013541323A (ja) | 2010-07-23 | 2013-11-14 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 貪食細胞を用いて疾患または症状のシグネチャを検出する方法 |
EP2611832B1 (en) | 2010-09-02 | 2017-11-29 | Vaccinex, Inc. | Anti-cxcl13 antibodies and methods of using the same |
EP2648750B1 (en) * | 2010-12-10 | 2017-01-25 | Novartis AG | Antibody formulation |
ME02734B (me) | 2011-01-14 | 2017-10-20 | Ucb Biopharma Sprl | Antitelo koje vezuje il-17a i il-17f |
SG193514A1 (en) | 2011-04-01 | 2013-10-30 | Immunogen Inc | Methods for increasing efficacy of folr1 cancer therapy |
EP2700653B1 (en) * | 2011-04-15 | 2019-07-24 | SNU R&DB Foundation | Complex in which anti-cotinine antibody is bound to conjugate of cotinine and binding substance, and use therefor |
JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
MX2014004074A (es) | 2011-10-05 | 2014-06-05 | Genentech Inc | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. |
US9890213B2 (en) | 2012-03-02 | 2018-02-13 | Vaccinex, Inc. | Methods for the treatment of B cell-mediated inflammatory diseases |
US10481164B2 (en) * | 2012-03-26 | 2019-11-19 | Amgen Inc. | Method for using light scattering in real time to directly monitor and control impurity removal in purification processes |
EP2831115A1 (en) | 2012-03-27 | 2015-02-04 | F. Hoffmann-La Roche AG | Diagnosis and treatments relating to her3 inhibitors |
US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
WO2014036520A1 (en) | 2012-08-30 | 2014-03-06 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
KR102617499B1 (ko) | 2012-08-31 | 2023-12-22 | 이뮤노젠 아이엔씨 | 엽산 수용체 1의 검출을 위한 진단성 검정 및 키트 |
WO2014078280A1 (en) * | 2012-11-13 | 2014-05-22 | Genentech, Inc. | Enrichment of antigen-specific plasmablasts |
KR102176962B1 (ko) | 2013-01-31 | 2020-11-10 | 백시넥스 인코포레이티드 | 면역글로불린 a 수준을 증가시키기 위한 방법 |
US11585814B2 (en) | 2013-03-09 | 2023-02-21 | Immunis.Ai, Inc. | Methods of detecting prostate cancer |
US10494675B2 (en) | 2013-03-09 | 2019-12-03 | Cell Mdx, Llc | Methods of detecting cancer |
SG11201507477XA (en) | 2013-03-14 | 2015-10-29 | Genentech Inc | Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use |
US20160053023A1 (en) | 2013-04-09 | 2016-02-25 | Annexon, Inc. | Methods of treatment for neuromyelitis optica |
EP3019240B1 (en) | 2013-07-09 | 2024-03-13 | Annexon, Inc. | Anti-complement factor c1q antibodies and uses thereof |
CN105814079B (zh) | 2013-08-30 | 2021-02-09 | 伊缪诺金公司 | 用于检测叶酸受体1的抗体和测定 |
US10435474B2 (en) | 2013-12-24 | 2019-10-08 | Ossianix, Inc. | Baff selective binding compounds and related methods |
SG10201913611QA (en) | 2014-08-08 | 2020-03-30 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
WO2016040843A1 (en) | 2014-09-11 | 2016-03-17 | Harry Stylli | Methods of detecting prostate cancer |
EP3689910A3 (en) | 2014-09-23 | 2020-12-02 | F. Hoffmann-La Roche AG | Method of using anti-cd79b immunoconjugates |
KR102626877B1 (ko) | 2014-11-05 | 2024-01-19 | 애넥슨, 인코포레이티드 | 인간화 항-보체 인자 c1q 항체 및 이의 용도 |
ES2899227T3 (es) | 2015-04-07 | 2022-03-10 | Alector Llc | Anticuerpos anti sortilina y métodos de uso de los mismos |
KR20180020142A (ko) * | 2015-05-01 | 2018-02-27 | 인히브릭스 엘피 | Iii형 분비계 표적화 분자 |
CA2988982A1 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
WO2016201389A2 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
KR20180030518A (ko) | 2015-07-16 | 2018-03-23 | 인히브릭스 엘피 | 다가 및 다중특이적 dr5-결합 융합 단백질 |
US10590198B2 (en) | 2015-08-28 | 2020-03-17 | Alector Llc | Anti-siglec-7 antibodies and methods of use thereof |
CN108601828B (zh) | 2015-09-17 | 2023-04-28 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
KR20180068999A (ko) | 2015-10-06 | 2018-06-22 | 알렉터 엘엘씨 | 항-trem2 항체 및 그의 사용방법 |
EP3368575A2 (en) | 2015-10-29 | 2018-09-05 | Alector LLC | Anti-siglec-9 antibodies and methods of use thereof |
JP7023853B2 (ja) | 2016-03-04 | 2022-02-22 | アレクトル エルエルシー | 抗trem1抗体及びその使用方法 |
CN109641957B (zh) | 2016-06-06 | 2022-10-04 | 希望之城 | Baff-r抗体及其用途 |
JP7070932B2 (ja) * | 2016-06-06 | 2022-05-18 | シティ・オブ・ホープ | Baff-r標的化キメラ抗原受容体修飾t細胞及びその使用 |
EP3625258A1 (en) | 2017-05-16 | 2020-03-25 | Alector LLC | Anti-siglec-5 antibodies and methods of use thereof |
KR20200033798A (ko) | 2017-08-03 | 2020-03-30 | 알렉터 엘엘씨 | 항-cd33 항체 및 이의 이용 방법 |
BR112019022752A2 (pt) | 2017-08-03 | 2020-05-19 | Alector Llc | anticorpos anti-trem2 e métodos de uso dos mesmos |
EP3456737B1 (en) | 2017-09-19 | 2024-02-14 | Tillotts Pharma Ag | Antibody variants |
EP3456736B1 (en) | 2017-09-19 | 2021-04-07 | Tillotts Pharma Ag | Antibody variants |
EP3456738A1 (en) | 2017-09-19 | 2019-03-20 | Tillotts Pharma Ag | Antibody variants |
EP3456739A1 (en) | 2017-09-19 | 2019-03-20 | Tillotts Pharma Ag | Use of anti-tnfalpha antibodies for treating wounds |
MA50360A (fr) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences Inc | Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations |
US10344091B2 (en) | 2017-10-27 | 2019-07-09 | New York University | Anti-Galectin-9 antibodies and uses thereof |
MA52753A (fr) | 2018-05-25 | 2021-04-21 | Alector Llc | Anticorps anti-sirpa et leurs procédés d'utilisation |
BR112020024919A2 (pt) | 2018-06-08 | 2021-03-09 | Alector Llc | Anticorpos, ácido nucleico, vetor, célula hospedeira, métodos de produção de um anticorpo e de prevenção, redução do risco ou tratamento de câncer e composição farmacêutica |
KR20230065382A (ko) | 2018-07-13 | 2023-05-11 | 알렉터 엘엘씨 | 항-소틸린 항체 및 이들의 사용 방법 |
US20200140533A1 (en) | 2018-11-02 | 2020-05-07 | Annexon, Inc. | Compositions and methods for treating brain injury |
WO2020114616A1 (en) | 2018-12-07 | 2020-06-11 | Tillotts Pharma Ag | Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof |
WO2020154889A1 (zh) * | 2019-01-29 | 2020-08-06 | 上海鑫湾生物科技有限公司 | 具有Fc突变体的抗体与效应细胞的组合、用途和制法 |
EP3962954A4 (en) * | 2019-05-01 | 2023-01-18 | New York University | ANTI-GALECTIN-9 ANTIBODIES AND THEIR USES |
IL293386A (en) | 2019-12-05 | 2022-07-01 | Alector Llc | Methods for using anti-trem2 antibodies |
MX2022007156A (es) | 2019-12-12 | 2022-09-07 | Alector Llc | Metodos de uso de anticuerpos anti-cd33. |
WO2021173565A1 (en) | 2020-02-24 | 2021-09-02 | Alector Llc | Methods of use of anti-trem2 antibodies |
MX2022011752A (es) | 2020-03-24 | 2022-10-18 | Genentech Inc | Agentes de fijacion a tie2 y metodos de uso. |
JP2023520516A (ja) | 2020-04-03 | 2023-05-17 | アレクトル エルエルシー | 抗trem2抗体の使用方法 |
CN116903727A (zh) * | 2020-05-08 | 2023-10-20 | 高山免疫科学股份有限公司 | 具有和不具有t细胞抑制蛋白的april和baff抑制性免疫调节蛋白及其使用方法 |
CN112999346A (zh) * | 2021-03-04 | 2021-06-22 | 华中科技大学同济医学院附属协和医院 | Baff抗体在制备治疗炎症性肠病药物中的应用 |
WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
WO2023164516A1 (en) | 2022-02-23 | 2023-08-31 | Alector Llc | Methods of use of anti-trem2 antibodies |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2694002T3 (es) * | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
UA83458C2 (ru) * | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Выделенный полипептид baff-r (рецептор фактора активации в-клеток семейства tnf) |
CN1636067A (zh) * | 2001-08-03 | 2005-07-06 | 杰南技术公司 | TACls和BR3多肽及其用途 |
WO2003074679A2 (en) * | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
-
2005
- 2005-12-23 AU AU2005323025A patent/AU2005323025A1/en not_active Abandoned
- 2005-12-23 AP AP2007004034A patent/AP2007004034A0/xx unknown
- 2005-12-23 EA EA200701211A patent/EA200701211A1/ru unknown
- 2005-12-23 KR KR1020077017604A patent/KR20070107687A/ko not_active Application Discontinuation
- 2005-12-23 WO PCT/US2005/047072 patent/WO2006073941A2/en active Application Filing
- 2005-12-23 JP JP2007549554A patent/JP2008526205A/ja not_active Withdrawn
- 2005-12-23 BR BRPI0518994-2A patent/BRPI0518994A2/pt not_active Application Discontinuation
- 2005-12-23 MX MX2007008017A patent/MX2007008017A/es not_active Application Discontinuation
- 2005-12-23 CN CNA2005800443390A patent/CN101120021A/zh active Pending
- 2005-12-23 US US11/793,946 patent/US20080181888A1/en not_active Abandoned
- 2005-12-23 CA CA002595112A patent/CA2595112A1/en not_active Abandoned
- 2005-12-23 EP EP05857219A patent/EP1838735A2/en not_active Withdrawn
-
2007
- 2007-05-21 IL IL183353A patent/IL183353A0/en unknown
- 2007-05-29 NO NO20072721A patent/NO20072721L/no not_active Application Discontinuation
-
2010
- 2010-07-13 US US12/835,570 patent/US20100280227A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NO20072721L (no) | 2007-10-01 |
WO2006073941A3 (en) | 2006-08-31 |
US20080181888A1 (en) | 2008-07-31 |
CN101120021A (zh) | 2008-02-06 |
EP1838735A2 (en) | 2007-10-03 |
WO2006073941A2 (en) | 2006-07-13 |
IL183353A0 (en) | 2008-04-13 |
AU2005323025A1 (en) | 2006-07-13 |
AP2007004034A0 (en) | 2007-06-30 |
US20100280227A1 (en) | 2010-11-04 |
JP2008526205A (ja) | 2008-07-24 |
CA2595112A1 (en) | 2006-07-13 |
KR20070107687A (ko) | 2007-11-07 |
BRPI0518994A2 (pt) | 2008-12-02 |
WO2006073941A9 (en) | 2007-07-05 |
MX2007008017A (es) | 2007-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200701211A1 (ru) | Полипептиды, которые связываются с br3, и их применение | |
EA200801621A1 (ru) | Антитела, направленные на her-3, и их применение | |
EA200901436A1 (ru) | Антигенсвязывающие белки, связывающие par-2 | |
EA200702402A1 (ru) | Агенты, связывающие склеростин | |
MA32982B1 (fr) | Proteines de liaison au recepteur cgrp humain | |
EA201170312A1 (ru) | Селективные антитела к гепцидину-25 и их применение | |
EA201290570A1 (ru) | Конструкты, связывающиеся с ron, и способы их использования | |
EA201100694A1 (ru) | Антитело к cd38 человека и его применение | |
DE502005009389D1 (de) | Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern | |
EA200701448A1 (ru) | Специфически связывающаяся с крипто-антигеном человека молекула (варианты), композиция на ее основе (варианты), способ получения молекулы, способ лечения посредством молекулы (варианты) и способ ингибирования крипто-экспрессии в клетке больного | |
EA201070553A1 (ru) | Антитела к гепцидину и варианты их применения | |
EA201190041A1 (ru) | Человеческие аутоантитела против альфа-синуклеина | |
CL2011000010A1 (es) | Anticuerpo monoclonal anti-peptido beta-amiloide; polinucleotido que lo codifica; hibridoma; metodo de produccion; composicion que lo comprende; uso para tratar enfermedades relacionadas con proteinas amiloides; metodo de diagnostico de las mismas; y kit que lo comprende. | |
CO6280541A2 (es) | Anticuerpos monoclonales o fragmentos del mismo que se unen al recptor humano ox40 | |
MY174493A (en) | Binding agents | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
MX2008009886A (es) | Anticuerpos que enlazan par-2. | |
HK1074670A1 (en) | Sets of digital antibodies directed against short epitopes, and methods using same | |
EA200801174A1 (ru) | Антитела-миметики glp-2, полипептиды, композиции, способы и применения | |
DE602006013143D1 (de) | Verfahren zum nachweis aggregatbildender zirkulierender proteinformen und mittel zum einfangen gebildeter aggregate | |
BR112021018632A2 (pt) | Moléculas de ligação ao cd3 | |
EP2083018A3 (en) | Compositions and methods relating to STOP-1 | |
NZ589330A (en) | Interleukin-21 receptor binding proteins | |
WO2005094159A3 (en) | Methods of identifying neoplasm-specific antibodies and uses thereof | |
TW200718711A (en) | Polypeptides that bind BR3 and uses thereof |